N-methyl-D-aspartate antagonists for stroke and head trauma

Bibliography

• FAGG GE, FOSTER AC: Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience (1983) 9:701–719.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT, PORTER HP: Anatomy and physiology of glutamate in the CNS. Neurology (1994) 44\(Suppl. 8):S7–S13.
   Google Scholar
• GASIC GP, HOLLMANN M: Molecular neurobiology of glutamate receptors. Ann. Rev. Physiol (1992) 54:507–536.
   PubMed Web of Science ®Google Scholar
• SILVER B, WEBER J, FISHER M: Medical therapy for ischaemic stroke. Clin. Neuropharmacol (1996) 19:101–128.
   PubMed Web of Science ®Google Scholar
• TAYLOR TN, DAVIS PH, TORNER JC et al: Lifetime cost of stroke in the United States. Stroke (1996) 27:1459–1466.
   PubMed Web of Science ®Google Scholar
• BULLOCK R: Introducing NMDA antagonists into clinical practice: why head injury trials. Br. J. Clin. Pharmacol (1992) 34:396–401.
   PubMed Web of Science ®Google Scholar
• GERLACH M, RIEDERER P, YOUDIM MBH: Neuroprotec-tive therapeutic strategies. Comparison of experimen-tal and clinical results. Biochem. Pharmacol (1995) 50:1–16.
   Google Scholar
• LEHMANN JC, HUTCHINSON AJ, MCPHERSON SE etal: CGS19755, a selective and competitive NMDA-type excita-tory amino acid receptor antagonist. J. Pharmacol. Exp. Ther. (1988) 246:65–75.
   PubMed Web of Science ®Google Scholar
• BENNETT DA, LEHMANN J, BERNARD PS eta].: CGS 19755:a novel competitive N-methyl-D-aspartate (NMDA) re-ceptor antagonist with anticonvulsant, anxiolytic and anti-ischaemic properties. Prog Cl/n. Biol. Res. (1990) 361:519–524.
   Google Scholar
• ORNSTEIN PL, SCHOEPP DD, ARNOLD MB et al.: 6-Substi-tuted decahydroisoquinoline-3-carboxylic acids as po-tent and selective conformationally constrained NMDA receptor antagonists. J. Merl. Chem. (1992) 35:3547–3560.
   PubMed Web of Science ®Google Scholar
• ORNSTEIN PL, SCHOEPP DD, ARNOLD MB et al: NMDA antagonist activity of (±)-(2SR,4R5)-4-(1H-tetrazol-5-yl-methyflpiperidine-2-carboxylic acid resides with the (-)-2R, 4S-isomer. J. Mid. Chem. (1992) 35:3111–3115.
   PubMed Web of Science ®Google Scholar
• WHITTEN JP, BARON BH, MCDONALD IA: Competitive NMDA receptor antagonists: R-4-oxo-5-phosp ho nonor-va line structure-activity relationships. Bioorg. Med. Chem. Leff. (1993) 3:23–26.
   Web of Science ®Google Scholar
• FERKANY JW, WILLETTS J. BOROSKY DB et al: Pharma-cology of (2R, 4R, 5S)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 17742): a selective, systemically active, competitive NMDA antagonist. Bioorg Merl. Chem. Leff. (1993) 3:33–38.
   Web of Science ®Google Scholar
• HAYS SJ, BIGGE CF, NOVAK PM eta].: New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity rela-tionships and pharmacological evaluation. J. Med. Chem. (1990) 33:2916–2924.
   Google Scholar
• BIGGE CF: Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists. Biochem. Pharmacol (1993) 45:1547–1561.
   PubMed Web of Science ®Google Scholar
• LOWE DA, EMRE M, FREY P eta].: The pharmacology of SDZ FAA 494, a competitive NMDA antagonist. Neuro-chem. Int (1994) 25:583–600.
   Google Scholar
• CZUCWAR SJ, BOROWICZ KK, KLEINROK Z et al.: Influ-ence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. Eur. j Pharmacol. (1995) 281:327–333.
   PubMed Web of Science ®Google Scholar
• BULLOCK R, GRAHAM DI, CHEN M-H, LOWE D, MCCUL-LOCH J: Focal cerebral ischaemia in the cat: pretreat-ment with a competitive NMDA receptor antagonist, D-CPP-ene. J. Cereb. Blood Flow Metab. (1990) 10:668–674.
   PubMed Web of Science ®Google Scholar
• CHEN M, BULLOCK R, GRAHAM DI eta].: Evaluation of a competitive NMDA antagonist (D-CPPene) in feline fo-cal cerebral ischaemia. Ann. Neurol (1991) 30:62–70.
   Google Scholar
• SIMON R, HOGAN K: N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann. Neurol. (1990) 27:606–611.
   PubMed Web of Science ®Google Scholar
• SCATTON B: Excitatory amino acid receptor antago-nists: a novel treatment for ischaemic cerebrovascular diseases. Life Sci. (1994) 55:2115–2124.
   PubMed Web of Science ®Google Scholar
• SVEINBJORNSDOTTIR S, SANDER JWAS, UPTON D et al.:The excitatory amino acid antagonist D-CPP-ene (SBZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165–174.
   PubMed Web of Science ®Google Scholar
• GROTTA J, CLARK W, COULL B eta].: Safety and tolerabil-ity of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischaemic stroke: results of a Phase Ha randomized trial. Stroke (1995) 26:602–605.
   Google Scholar
• ELLISON G: Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport (1994) 5:2688–2692.
   PubMed Web of Science ®Google Scholar
• HOGAN MJ, GJEDDE A, HAKIM AM: In vivo distribution of CGS-19755 within brain in a model of focal cerebral ischaemia. j Neurochem. (1992) 58:186–191.
   PubMed Web of Science ®Google Scholar
• WONG EHF, KEMP JA, PRIESTLEY T: The novel anticon-vulsant MK801 is a potent N-methyl-D-aspartate antago-nist. Proc. Natl. Acad. Sci. USA (1986) 83:7104–7109.
   PubMed Web of Science ®Google Scholar
• ANNIS NA, BERRY SC, BUTON NR, LODGE D: The disso-ciative anesthetics, ketamine and phencyclidine selec-tively reduce excitation of central mammalian neurones by N-methyl-D-aspartate. Br. J. Pharmacol (1983) 79:565–575.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU M, CHO AK, NABESHIMA T: Comparison of the behavioural and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. (1989) 166:359–366.
   PubMed Web of Science ®Google Scholar
• WILLETTS J, BALSTER RL, LEANDER JD: The behavioural pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. (1990) 11:423–428.
   PubMed Web of Science ®Google Scholar
• ALLEN RM, YOUNG SJ: Phencyclidine-induced psycho-ses. Am. J. Psychiat (1978) 135:1081–1084.
   PubMed Web of Science ®Google Scholar
• TROUPIN AS, MENDIUS JR, CHENG F, RISINGER MW: MK-801. In: New Anticonvulsant Drugs Meldrum B, Porter R (Eds.), John Libbey, London. (1986) 191–201.
   Google Scholar
• KORNHUBER J, WELLER M: Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmwotherapy. Biol. Psych. (1997) 41:135–144.
   PubMed Web of Science ®Google Scholar
• FIX AS, HORN JW, TRUEX LL, SMITH RA, GOMEZ E: Neuronal vacuole formation in the rat posterior cingu-late/retrosplenial cortex after treatment with the N-methyl-D-aspartate (NMDA) antagonist MK-801 (dizocilpine maleate). Ada. Neuropathol. (1994) 88:511–519.
   PubMed Web of Science ®Google Scholar
• OZYURT E, GRAHAM DI, WOODRUFF GN, MCCULLOCH J:The protective effect of the glutamate antagonist MK-801 in focal cerebral ischaemia in the cat J. Cereb. Blood How Metab. (1988) 8:138–143.
   PubMed Web of Science ®Google Scholar
• MUIR KW, GROSSET DG, GAMSU E, LEES KR: Pharma-cological effects of the non-competitive NMDA antago-nist CERESTAT® in normal volunteers. Br. J. Pharmacol (1994) 38:33–38.
   Web of Science ®Google Scholar
• MEADOWS M-E, FISHER M, MINEMATSU K: Delayed treat-ment with a non-competitive NMDA antagonist, CNS-1102, reduces infarct size in rats. Cerebrovasc. Dis. (1994) 4:26–31.
   Web of Science ®Google Scholar
• SCRIP (1996) 2164:27.
   Google Scholar
• GROSSET DG, MUIR KW, LEES KR: Systemic and cerebral hemodynamic responses to the nan-competitive N-methyl-D--aspartate (NMDA) antagonist CNS 1102. J. Cardiovasc. Pharmacol (1995) 25:705–709.
   PubMed Web of Science ®Google Scholar
• CARRON C, JULLIEN A, BUCHER B. Synthesis and phar-macological properties of a series of 2-piperidino al-kanol derivatives. Arz.-Forsch. (1971) 21:1992–1998
   Google Scholar
• YOUNG AR, BOULOY M, BOUSARD J-F et al: Directvascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. Cereb. Blood Flow Metab. (1981) 1:117–126.
   PubMed Web of Science ®Google Scholar
• CHATELAIN P, FRIEDHOFF AJ, MELLER E eta].: Receptor binding profile of tibalosine, a new antihypertensive. Aix. -Forsch. (1984) 34:754–758.
   Google Scholar
• RAO TS, CLER J, EMMETT MR et al: Ifenprodil and SL 82.0715 antagonize N-methyl-D-aspartate (NMDA)-cou-pled glycine receptor responses in viva Eur. J Pharma-col. (1989) 168:129–131.
   Google Scholar
• BEART PM, MERCER LD, CONWAY EL, SEARLE AJ: Polyamine-sensitive binding of [1251]ifenprodil in washed, frozen-thawed synaptic membranes: evidence for high affinity binding requiring an open NMDA channel. Neurosci. Lett. (1992) 142:219–222.
   PubMed Web of Science ®Google Scholar
• WILLIAMS K: Ifenprodil discriminates subtypes of the N-methyl-u-aspartate receptor: selectivity and mecha-nisms at recombinant heteromeric receptors. Ma Phar-macol (1993) 44:851–859.
   PubMed Web of Science ®Google Scholar
• AVENET P, LEONARDON J, BESNARD F et al: Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur. j Pharma-col. (1996) 296:209–213.
   PubMed Web of Science ®Google Scholar
• NICOLAS C, CARTER C: Autoradiographic distribution and characteristics of high- and low-affinity polyamine-sensitive [311]ifenprodil sites in the rat brain: possible relationship to NMDAR2B receptors and calmodulin. J. Neurochem. (1994) 63:2248–2258.
   PubMed Web of Science ®Google Scholar
• CHENARD BL, SHALABY BK, KOE RT et al: Separation of al adrenergic and N-methyl-D-aspartate antagonist ac-tivity in a series of ifenprodil compounds. J. Med. Chem. (1991) 34:3085–3090.
   PubMed Web of Science ®Google Scholar
• CHENARD BL, BORDNER J, BUTLER TW et al: (1S,25)-1-(4-Hydr oxyp he nyl) -2- (4-hydroxy-4-phenylpiperidino) -1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. (1995) 38:3138–3145.
   PubMed Web of Science ®Google Scholar
• Drugs Future (1994) 19:905.
   Google Scholar
• BITON B., GRANGER P, CARREAU A et al: The NMDA receptor antagonist eliprodil (SL 82.0715) blocks volt-age-gated Ca2+ channels in rat cultured cortical neu-rones. Eur. j Pharmacol. 1994) 257:297–301.
   Google Scholar
• LESAGE AS, PEETERS L, LEYSEN JE: Lubehuole, a novel long-term neuroprotectant, inhibits the glutamate-acti-vated nitric oxide synthase pathway. J. Pharmacol Exp. Ther. (1996) 279:759–766.
   PubMed Web of Science ®Google Scholar
• ARONOWSKI J, STRONG R, GROTTA JC: Treatment ofexperimental focal ischaemia in rats with lubehzole. Neuropharmacology (1996) 35:689–693.
   PubMed Web of Science ®Google Scholar
• DIENER HC, HACKE W, HENNERICI M et al: Lubeluzole in acute ischaemic stroke - a double-blind, placebo-con-trolled Phase II trial. Stroke (1996) 27:76–81.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA A, NI C., ARITA J. et al: Effects of the antihy-poxic and neuroprotective drug, lubeluzole, on repo-larisation phase of canine heart assessed by monophasic action potent ial recording. Tox. Appl. Phar-macol (1996) 139:109–114.
   Google Scholar
• WHITTEMORE ER, ILYIN VI, WOODWARD RM: Antago-nism of N-methyl-D-aspartate receptors by a (sigma) site ligands: potency, subtype selectivity, and mecha- nisms of inhibition. J. Pharmacol. Exp. Ther. (1997) (Sub-mitted).
   Google Scholar
• MOTT DD, ZHANG S, WASHBURN MS et al: CP-101,606antagonizes NMDA receptors by interacting with the polyamine modulatory site. Soc. Neurosci. Abstr. (1996) 22:35.15.
   Google Scholar
• WOODWARD R, TRAN M: Personal communication.
   Google Scholar
• GOTTI B, DUVERGER D, BERTIN J et al.: Ifenprodil and SL 82.0715 as cerebralanti-ischaemic agents. L Evidence for efficacy in models of focal cerebral ischaemia. Pharmacol Exp. Ther. (1988) 247:1211–1216.
   Google Scholar
• KEMP JA, LEESON PD: The glycine site of the NMDA receptor five years later. Trends Pharmacol. Sci. (1993) 14:20–25.
   PubMed Web of Science ®Google Scholar
• HUETTNER JE: Competitive antagonism of glycine at the N-methyl-D--aspartate (NMDA) receptor. Biochem. Phar-macol. (1991) 41:9–16.
   PubMed Web of Science ®Google Scholar
• LEESON PD, IVERSEN LL: The glycine site on the NMDA receptor: structure-activity relationships and the rap eu-tic potential. J. Med. Chem. (1994) 37:4053–4067.
   PubMed Web of Science ®Google Scholar
• WOOD PL, RAO TS, IYENGAR S et al: A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel teceptor macrocom-plex. Neurochem. Res. (1990) 15:217–230.
   PubMed Web of Science ®Google Scholar
• THOMSON AM: Glycine is a co-agonist at the NMDA receptor/channel complex. Prog. Neurobiol (1990) 35:53–74.
   PubMed Web of Science ®Google Scholar
• WOOD PL: The co-agonist concept: is the NMDA-associ-ated glycine receptor saturated in vivo? Life Sci (1995) 57:301–310.
   PubMed Web of Science ®Google Scholar
• BARE TM, SPARKS RB, SCHREFFLER-SMITH CN et al: 2-Aryl pyridazinoquinolinediones: novel glycine site NMDA antagonists with potent in vitro and in vivo properties. 211th American Chemistry SocietyNational Meeting (1996).
   Google Scholar
• XUE D, HUANG Z-G, BARNES K et al.: Delayed treatment with AMPA, but not NMDA, antagonists reduces neocor-tical infarction. J. Cereb. Blood Flow Metab. (1994) 14:251–261.
   PubMed Web of Science ®Google Scholar
• BALSTER RL, MANSBACH RS, SHELTON KL et al.: Behav-ioural pharmacology of two novel substituted quinox-alinedione glutamate antagonists. Behav. Pharmacol (1995) 6:577–589.
   PubMed Web of Science ®Google Scholar
• HAWKINSON JE, HUBER KR, SAHOTA PS et al: The N-methyl-u-aspartate (NMDA) receptor glycine site an-tagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res (1997) 744:227–234.
   PubMed Web of Science ®Google Scholar
• MORIMOTO MY, PEARLSTEIN Y, BRINKHOUS A, WARNER D. Effects of antagonism at the glycine recognition site of the N-methyl-D--aspartate receptor on cerebral me-tabolic rate for glucose utilization in the rat. 6th Inter-national Symposium on Pharmacology of Cerebral Ischaemia (1996).
   Google Scholar
• WARNER DS, MARTIN H, LUDWIG P et al: In vivo models of cerebral ischaemia: effects of parenterally adminis-tered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. (1995) 15:188–196.
   PubMed Web of Science ®Google Scholar
• WHITEHOUSE MJ, NAVALTA L, DENSEL M et al.: Initial clinical experience with ACEA 1021: safety, tolerance, and pharmacokinetics in healthy volunteers. North American Stroke Meeting (1996).
   Google Scholar
• ALBERS GW, CLARK WM, ATKINSON RP et al: Dose esca-lation study of the NMDA glycine-site antagonist ACEA 1021 in acute ischaemic stroke. 22nd International Joint Conference on Stroke and Cerebral Circulation (1997).
   Google Scholar
• CAI SX, KHER SM, ZHOU Z-L et al: Structure-activity relationships of alkyl and alkoxy substituted 1,4-dihy-droquinoxaline-2,3-diones: potent and systemically ac-tive antagonists for the glycine ite of the NMDA receptor. J. Med. Chem. (In Press).
   Google Scholar
• WOOD WARD RM, HUETTNER JE, TRAN M et al: Pharma-cology of 5-chloro-7-trifluoromethy1-1,4-dihydro-2,3-quinoxalinedione : a novel systemically active ionotropic glutamate receptor antagonist. J. Pharmacol Exp. Ther. (1995) 275:1209–1218.
   PubMed Web of Science ®Google Scholar
• BUNNEMANN B, CARIGNANI C, PALEA S et al.: In vitrocharacterization of a novel NMDA receptor glycine site antagonist: GV 150526A. Soc. NeuroscL AbsL (1996) 22:366.15.
   Google Scholar
• PIETRA C, BORDI F, REGGIANI A: The glycine antagonist GV 150526A protects somatosensory evoked potentials and reduces the infarct area inthe MCAO model of focal ischaemia in the rat. Soc. NeuroscL Absfr. (1996) 22:366.13.
   Google Scholar
• MARVIZON JC, LEWIN AK, SKOLNICK P: 1-Aminocyclo-propane carboxylic add a potent and selective ligand for the glycine modulatory site of the N-methyl-D-as par - tate receptor complex. J. Neurochem. (1989) 52:992–996.
   PubMed Web of Science ®Google Scholar
• WATSON G, LANTHORN T: Pharmacological charac-teristics of cyclic homologues of glycine at the N-methyl-D-aspartate receptor associated glycine site. Neuropharmacology (1990) 29:727–730.
   PubMed Web of Science ®Google Scholar
• RAO TS, CLER JA, COMPTON RP et al: Neuropharma-cological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. Neuropharmacology (1990) 29:305–309.
   PubMed Web of Science ®Google Scholar
• VON LUBITZ DKJE, LIN RC-S, MCKENZIE RJ et al: A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur. J. Pharmacol (1992) 219:153–158.
   PubMed Web of Science ®Google Scholar
• ZAPATA A, CAPDEVILA JL, VIU E, TRULLAS R: 1-Aminocy-clopropane -carboxylic acid reduces NMDA-induced hippocampal neurodegeneration in vivo. Neuroreport (1996) 7:397–400.
   PubMed Web of Science ®Google Scholar
• TRULLAS R, FOLIO T, YOUNG A et al.: 1-Aminocyclo-propanecarboxylates exhibit antidepressant and anx-iolytic actions in animal models. Eur.J. Pharmacol. (1991) 203:379–385.
   PubMed Web of Science ®Google Scholar